琉球大学病院は、沖縄県中頭郡西原町にあり、琉球大学医学部に附属する大学病院である。沖縄県で唯一、また、日本最南端かつ最西端の大学病院である。特定機能病院の承認を受けるほか、都道府県がん診療連携拠点病院、エイズ治療拠点病院、肝疾患診療連携拠点病院に指定されている。

During the past decade, University of the Ryukyus Hospital conducted 8 clinical trials. In the 10-year time frame, 8 clinical trials started and 3 clinical trials were completed, i.e. on average, 37.5% percent of trials that started reached the finish line to date. In the past 5 years, 4 clinical trials started and 3 clinical trials were completed. i.e. 75% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of the Ryukyus Hospital" #1 sponsor was "Takeda" with 3 trials, followed by "Daiichi Sankyo Co., Ltd." with 2 trials sponsored, "Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan" with 2 trials sponsored, "Bayer" with 1 trials sponsored and "National Cancer Center Hospital East" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of the Ryukyus Hospital" #1 collaborator was "Niigata University Medical & Dental Hospital" with 2 trials as a collaborator, "Alpha-A, Inc." with 1 trials as a collaborator, "Daiichi Sankyo, Inc." with 1 trials as a collaborator, "Regeneron Pharmaceuticals" with 1 trials as a collaborator and "Sanofi" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "University of the Ryukyus Hospital" are "Fallopian Tube Cancer" (2 trials), "Gastrointestinal Stromal Tumor" (2 trials), "Metastatic Cancer" (2 trials), "Ovarian Cancer" (2 trials) and "Primary Peritoneal Cancer" (2 trials). Many other conditions were trialed in "University of the Ryukyus Hospital" in a lesser frequency.

Most popular intervention types in "University of the Ryukyus Hospital" are "Drug" (9 trials) and "Procedure" (1 trials). Other intervention types were less common.

The name of intervention was led by "Niraparib" (2 trials), "Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)" (1 trials), "Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)" (1 trials), "Cemiplimab" (1 trials) and "DS-3201b" (1 trials). Other intervention names were less common.

The vast majority of trials in "University of the Ryukyus Hospital" are 7 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "University of the Ryukyus Hospital". undefined are not yet recruiting, 1 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in University of the Ryukyus Hospital, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in University of the Ryukyus Hospital, 1 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".